Desvenlaxafine succinate monohydrate
-Desvenlafaxine succinate monohydrate is a synthetic form of the antidepressant drug desvenlafaxine, which belongs to the serotonin-norepinephrine reuptake inhibitor (SNRI) class. It works by increasing the levels of serotonin and norepinephrine in the brain, helping to restore the balance of these neurotransmitters. -Desvenlaxafine, serotonin and norepinephrine reuptake inhibitor (SNRI), is the major active metabolite of the antidepressant venlafaxine.-Desvenlafaxine is primarily prescribed for the treatment of major depressive disorder (MDD) in adults. It is also used to relieve the symptoms of generalized anxiety disorder (GAD). -Major depressive disorder (MDD)
-The dosage of desvenlafaxine succinate monohydrate varies based on the individual patient and their specific condition. It is essential to follow the prescribed dosage and administration instructions provided by the healthcare professional. -Oral; 50mg per day (dosage vary from 25 mg to 400mg in clinical studies)
-Desvenlafaxine should not be used in patients who have a known hypersensitivity to the drug or its components. It is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing treatment with an MAOI. -Hypersensitivity
-Special precautions should be taken in patients with a history of bipolar disorder, as desvenlafaxine may trigger a manic episode. Close monitoring is necessary in individuals with a history of seizures, liver or kidney impairment, and those at risk of hyponatremia (low sodium levels). Paediatric: Safety and efficacy in pediatric patients have not been established. Pregnancy: Category C; It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: Desvenlaxafine is excreted in human milk. Because of potential for adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Elderly: Increased risk of hyponatremia.
-Special precautions should be taken in patients with a history of bipolar disorder, as desvenlafaxine may trigger a manic episode. Close monitoring is necessary in individuals with a history of seizures, liver or kidney impairment, and those at risk of hyponatremia (low sodium levels). Paediatric: Safety and efficacy in pediatric patients have not been established. Pregnancy: Category C; It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: Desvenlaxafine is excreted in human milk. Because of potential for adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Elderly: Increased risk of hyponatremia.
-Desvenlafaxine may interact with other medications, such as MAOIs, linezolid, lithium, and certain other antidepressants. It is important to inform the healthcare provider about all medications, including over-the-counter drugs and herbal supplements, being taken concurrently. -MAO Inhibitors, linezolid, intravenous methylene blue, other SNRIs, anticoagulants.
